Report from South Korea - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Report from South Korea
The bio-pharmaceutical business outlook in South Korea remains positive.


Pharmaceutical Technology
Volume 37, Issue 8, pp. 36-37

Moving forward in South Korea
South Korea has sustained rapid growth, low debt, and resilience to global financial stress. South Korea's high-quality healthcare system has stimulated demand for medical tourism with strong government support. Implementation of free-trade agreements with the EU and US will likely have a considerable positive impact on the healthcare market through IP protection, opening of access to the single-payer government system, and a reduction in trade tariffs (estimated to eliminate 95% of tariffs within five years). Overall, the pharmaceutical and biotech business outlook in South Korea remains positive.

On the flip side, manufacturers will need to keep a close eye on reimbursement reform as it progresses, and be prepared to provide both strong clinical and economic data to justify pricing and market access.

REFERENCES
1. WHO, Global Health Expenditure Database, World Health Organisation, 2010, http://apps.who.int/nha/database/PreDataExplorer.aspx?d=1, accessed July, 22 2013.
2. Korean Pharmaceutical Traders Association, Korea's Top 10 Exporting Markets, Korean Pharmaceutical Traders Association (2010), http://www.kpta.or.kr/eng/Info/statistics_export.asp
3. Seo, Eunking, Bloomberg BusinessWeek, (21 Feb., 2013), http://www.businessweek.com/articles/2013-02-21/south-koreas-hottest-import-foreign-workers, accessed July, 22 2013.
4. Chung, Seung. Minister's Message. Ministry of Food and Drug Safety, 2013.
5. Kim, So-Hyun, The Korea Herald (Aug. 17, 2011), http://www.koreaherald.com/view.php?ud=20110812000778, accessed 22 July, 2013.
6. Seo, Eun-kyung, Reuters (July 15, 2009), http://www.reuters.com/article/2009/07/15/us-samsung-bio-idUSTRE56E0ZP20090715, accessed July 22, 2013.
7. Office of the United States Trade Representative. Press Release (21 Feb., 2012).
8. PhRMA. Press Release, Feb. 21, 2012.
9. Yang BM, Bae EY, Kim J. Health Affairs, (2008) Jan-Feb;27(1):179-87. doi: 10.1377/hlthaff.27.1.179.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here